AstraZeneca Pharma
add_icon

AstraZeneca Pharma

8,401.00
-208.00
(-2.42%)
Market Cap
21,002.50 Cr
PE Ratio
107.00
Volume
6,947.00
Day High - Low
8,579.00 - 8,292.00
52W High-Low
10,691.00 - 7,201.15
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
21,002.50 Cr
EPS
46.30
PE Ratio
107.00
PB Ratio
26.91
Book Value
319.60
EBITDA
294.60
Dividend Yield
0.37 %
Industry
Healthcare
Return on Equity
15.02
Debt to Equity
0.03
Forecast For
Actual

Company News

View All News
Caret
neutral
AstraZeneca Pharma India submitted regulatory compliance certificate to stock exchanges confirming adherence to SEBI dematerialization regulations for February 2026 period.
positive
AstraZeneca Pharma India Limited has appointed Mrs. Sandhya Tejaswini Amanna as Director - Legal, effective March 18, 2026. She brings over two decades of experience in manufacturing, FMCG, and pharmaceutical sectors.
neutral
AstraZeneca Pharma India Limited announces postal ballot for shareholder approval of material related party transactions worth ₹3,900 crore with UK and Swedish entities for FY27.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,801.60
#1 4,32,264.19
39.98
#1 54,729.00
9.71
#1 10,980
16.07
62.14
6,071.00
1,61,165.97
67.21
9,712.00
18.67
2,191
-1.02
38.37
4,390.00
1,48,577.55
66.21
11,539.40
6.99
1,911
26.24
61.73
1,292.30
1,07,859.28
19.93
33,741.20
16.73
5,725
-15.28
51.79
1,314.70
1,06,197.76
23.61
28,409.50
7.12
5,291
-57.18
40.42
2,314.90
1,05,744.36
23.07
22,909.50
13.74
3,306
#1 37.44
57.99
905.90
91,154.74
#1 18.35
23,511.00
18.55
4,615
-0.32
48.43
2,138.90
88,294.88
50.56
12,744.20
#1 20.90
2,007
7.65
47.71
1,296.50
75,300.93
21.89
32,345.60
9.43
3,484
7.59
66.14
5,355.50
64,033.04
26.89
13,458.30
3.70
2,216
1.90
40.57
Growth Rate
Revenue Growth
32.07 %
Net Income Growth
-28.36 %
Cash Flow Change
134.52 %
ROE
-33.80 %
ROCE
-36.77 %
EBITDA Margin (Avg.)
1.76 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
523
571
558
583
745
845
826
820
1,029
1,330
1,757
2,218
Expenses
529
547
507
525
657
711
678
719
838
1,111
1,462
1,901
EBITDA
-6
23
51
59
88
134
148
101
191
219
295
316
Operating Profit %
-2 %
3 %
7 %
8 %
10 %
15 %
17 %
11 %
16 %
14 %
15 %
13 %
Depreciation
15
17
16
15
15
19
20
17
16
15
40
41
Interest
0
0
0
0
0
1
1
1
1
1
2
3
Profit Before Tax
-21
6
36
44
73
114
127
83
134
220
156
273
Tax
0
1
15
18
18
42
34
21
35
58
41
68
Net Profit
-21
5
20
26
54
72
93
62
99
162
116
201
EPS in ₹
-8.34
2.10
8.00
10.40
21.80
28.90
37.30
24.60
39.70
64.60
46.30
80.40

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
412
403
416
461
562
706
775
857
985
1,078
1,518
Fixed Assets
101
97
87
76
75
72
81
75
69
67
64
Current Assets
263
267
252
321
405
542
619
706
836
933
1,342
Capital Work in Progress
12
6
5
4
7
24
4
2
1
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
298
299
324
382
480
611
690
780
915
1,011
1,454
Total Equity & Liabilities
412
403
416
461
562
706
775
857
985
1,078
1,518
Current Liabilities
260
234
190
207
259
327
304
333
384
357
703
Non Current Liabilities
1
13
2
7
2
15
15
13
12
9
45
Total Equity
151
156
223
247
301
364
456
511
589
712
770
Reserve & Surplus
146
151
218
242
296
359
451
506
584
707
765
Share Capital
5
5
5
5
5
5
5
5
5
5
5

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-64
53
38
-1
59
-90
269
96
52
5
31
Investing Activities
-19
-4
0
-9
4
-171
173
5
18
22
31
Operating Activities
-46
57
38
9
55
87
105
101
58
28
65
Financing Activities
0
-1
0
0
0
-6
-9
-10
-25
-44
-66

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.69 %
0.00 %
2.74 %
2.79 %
2.90 %
2.93 %
2.89 %
3.03 %
2.74 %
2.71 %
DIIs
0.83 %
0.94 %
0.96 %
1.00 %
1.02 %
1.10 %
1.12 %
1.44 %
1.42 %
1.93 %
2.43 %
2.75 %
3.78 %
5.01 %
5.10 %
5.22 %
4.65 %
4.56 %
5.26 %
5.56 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
19.53 %
19.72 %
19.69 %
19.44 %
19.06 %
18.62 %
18.54 %
18.56 %
18.46 %
18.12 %
17.44 %
17.09 %
16.33 %
15.00 %
14.77 %
14.62 %
15.16 %
15.18 %
14.39 %
14.14 %
Others
4.64 %
4.34 %
4.34 %
4.57 %
4.92 %
5.28 %
5.34 %
5.01 %
5.12 %
4.95 %
2.44 %
5.15 %
2.15 %
2.20 %
2.23 %
2.24 %
2.31 %
2.23 %
2.61 %
2.59 %
No of Share Holders
0
63,753
68,077
66,444
62,183
57,760
53,980
49,085
42,146
38,946
32,380
29,032
29,418
27,169
27,615
27,322
32,466
34,378
32,914
31,551

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 1 2 10 16 24 32 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.03 0.08 0.31 0.3 0.28 0.38 0.00

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20182 days ago
Closure of Trading Window2 days ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel4 days ago
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 19, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Feb 19, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Disclosure Of ESG RatingFeb 18, 2026
Outcome Of The Board Meeting Held On Wednesday February 11 2026Feb 11, 2026
Appointment of Company Secretary and Compliance OfficerFeb 11, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Feb 10, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Disclosure Of ESG RatingFeb 02, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jan 31, 2026
Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results Of The Company For The Quarter Ended December 31 2025.Jan 31, 2026
Announcement under Regulation 30 (LODR)-Resignation of DirectorJan 29, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 16, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 16, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 16, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management PersonnelJan 09, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Dec 17, 2025
Closure of Trading WindowDec 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Dec 08, 2025
Determination Of Materiality - Details Of Key Managerial PersonnelDec 08, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 27, 2025
Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 18, 2025
Intimation About Second Brand Partnership Between Astrazeneca Pharma India Limited ("Company") And Sun Pharmaceuticals Industries Limited For Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5 GNov 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Nov 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerNov 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2025
Outcome Of The Board Meeting Held On Friday November 7 2025Nov 07, 2025
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Friday November 7 2025Oct 27, 2025
Launch Of Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5G (Lokelma)Oct 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Oct 03, 2025
Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 19, 2025
Closure of Trading WindowSep 12, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 12, 2025
Disclosure under Regulation 30A of LODRSep 12, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Sep 10, 2025
Disclosure under Regulation 30A of LODRSep 02, 2025
Disclosure under Regulation 30A of LODRSep 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 18, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 14, 2025
Outcome Of The Board Meeting Held On Thursday August 14 2025Aug 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Aug 12, 2025
Launch Of Eculizumab (Soliris)Aug 06, 2025
Clarification On News Item Appearing In Https://Www.Moneycontrol.ComAug 01, 2025
Clarification sought from AstraZeneca Pharma India LtdAug 01, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Quality Fund Direct-Growth
2.84%
5032
0.32%
0.36%
ICICI Prudential Active Momentum Fund Direct-Growth
1.15%
4005
0.14%
0.16%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.10%
74
0.10%
0.10%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
73
0.01%
0.01%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
0.90%
13
0.04%
0.03%
Nippon India Nifty 500 Quality 50 Index Fund Direct-Growth
0.91%
9
0.05%
0.00%
Angel One Nifty Total Market Momentum Quality 50 Index Fund Direct - Growth
0.34%
-4
0.00%
-0.01%
Axis Nifty500 Quality 50 Index Fund Direct-Growth
0.89%
3
0.04%
0.01%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.28%
3
0.01%
0.00%
DSP Nifty 500 Index Fund Direct-Growth
0.02%
-1
-0.01%
0.02%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.10%
-1
0.01%
0.00%
ICICI Prudential MNC Fund Direct - Growth
0.50%
0
0.00%
0.02%
ICICI Prudential Retirement Fund - Hybrid Aggressive Plan Direct - Growth
1.44%
0
0.00%
0.00%
Bandhan Small Cap Fund Direct-Growth
0.03%
0
0.00%
-0.02%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
4.07%
0
-0.01%
0.07%
Baroda BNP Paribas Manufacturing Fund Direct - Growth
2.63%
0
0.00%
-0.02%
Baroda BNP Paribas Small Cap Fund Direct - Growth
2.47%
0
0.00%
0.11%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.29%
0
0.00%
0.01%
Bandhan Large Cap Fund Direct-Growth
0.71%
0
0.00%
0.05%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
0.00%
0
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.28%
0
0.00%
0.00%
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth
0.39%
0
0.00%
0.02%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
0
0.00%
0.01%
Groww Nifty Total Market Index Fund Direct - Growth
0.03%
0
0.00%
0.00%
Groww Value Fund Direct-Growth
0.47%
0
0.00%
0.01%

Technical Indicators

RSI(14)
Neutral
35.69
ATR(14)
Volatile
221.04
STOCH(9,6)
Neutral
53.70
STOCH RSI(14)
Neutral
22.82
MACD(12,26)
Bearish
-41.76
ADX(14)
Weak Trend
22.34
UO(9)
Bearish
57.85
ROC(12)
Downtrend And Accelerating
-4.54
WillR(14)
Oversold
-83.41

About AstraZeneca Pharma

AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for...more
Chairperson NameShilpa Divekar Nirula